Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Epizyme closes $40mm Series B round

Executive Summary

New investor Bay City Capital led a $32mm Series B round for cancer therapeutics developer Epizyme. Also participating were additional new buyers Amgen Ventures and Astellas Venture Management, as well as returning backers Kleiner Perkins Caufield & Byers and MPM Capital. Bay City's managing director will take a seat on Epizyme's board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register